Cairo, 19th of February 2025 – Takeda has announced the launch of TAKHZYRO (Lanadelumab) in Egypt, the new therapy is intended for patients aged two years and older, administered as subcutaneous injections every two or four weeks for life. Its launch is part of Takeda’s efforts to provide therapeutic solutions for patients suffering from this […]

The post Takeda Launches TAKHZYRO (Lanadelumab) in Egypt: A New Treatment for Hereditary Angioedema Patients appeared first on Identity Magazine.